Flunixin

Flunixin

SCHEMBL29439899

Cc1c(Nc2ncccc2C(=O)O)cccc1C(F)(F)F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 8/20 1.00
HDAC6 Q9UBN7 1/20 1.00
CYP1A2 P05177 2/20 0.71
HIF1A Q16665 2/20 0.71
TSHR P16473 1/20 0.71
TAS2R14 Q9NYV8 2/20 0.68
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
LMNA P02545 3/20 0.56
PKM P14618 2/20 0.56
ALDH1A1 P00352 2/20 0.56
GMNN O75496 1/20 0.56
TTR P02766 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
NFKB1 P19838 1/20 0.56
UGT1A1 P22309 1/20 0.56
PTGS1 P23219 1/20 0.56
PTGS2 P35354 1/20 0.56
PMP22 Q01453 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flunixin SCHEMBL42911 1.00 DHODH (1.00) DHODHHDAC6CYP1A2HIF1ATSHR
Flunixin SCHEMBL31696761 1.00 DHODH (1.00) DHODHHDAC6CYP1A2HIF1ATSHR
Flunixin SCHEMBL8325584 1.00 DHODH (1.00) DHODHHDAC6CYP1A2HIF1ATSHR
Flunixin SCHEMBL28754969 0.99 DHODH (0.98) DHODHHDAC6CYP1A2HIF1ATSHR
Flunixin SCHEMBL4117904 0.99 DHODH (0.98) DHODHHDAC6CYP1A2HIF1ATSHR
Flunixin SCHEMBL28644103 0.98 DHODH (0.95) DHODHHDAC6CYP1A2HIF1ATSHR
Flunixin SCHEMBL27694863 0.95 DHODH (0.91) DHODHHDAC6CYP1A2HIF1ATSHR
Flunixin SCHEMBL7164324 0.93 DHODH (0.87) DHODHHDAC6CYP1A2HIF1ATSHR
Flunixin SCHEMBL29811437 0.92 DHODH (0.84) DHODHHDAC6CYP1A2HIF1ATSHR
SCHEMBL11485538 0.88 DHODH (0.78) DHODHHDAC6CYP1A2HIF1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
EP-3699174-B1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2025-11-12 EP claimed
EP-4518682-A1 USE OF NON-THERAPEUTIC ANTI-INFLAMMATORY MOLECULES IN PIGS Vetoquinol SA (FR) 2025-03-12 EP claimed
EP-3946461-B1 XYLOGLUCAN-CONTAINING PRODRUGS AND METHODS OF MANUFACTURE AND USE THEREOF UNIV BRITISH COLUMBIA (CA) 2025-01-15 EP claimed
CN-116813537-B Preparation method and application of novel flunixin hapten 深圳市绿诗源生物技术有限公司 2024-09-17 CN claimed
WO-2023214131-A1 USE OF NON-THERAPEUTIC ANTI-INFLAMMATORY MOLECULES IN PIGS VETOQUINOL SA (FR) 2023-11-09 WO claimed
CN-110327294-B Compound long-acting injection containing enrofloxacin and flunixin and preparation method thereof 南京农业大学 2023-06-13 CN claimed
CN-115710217-B Flunixin meglumine synthesis method suitable for industrial production 江苏恒盛药业有限公司 2025-06-13 CN disclosed
WO-2025122600-A1 COMPOSITIONS AND METHODS FOR TREATING ABERRANT NITROSYLATION CASE WESTERN RESERVE UNIVERSITY (US) 2025-06-12 WO disclosed
EP-4518682-A1 USE OF NON-THERAPEUTIC ANTI-INFLAMMATORY MOLECULES IN PIGS Vetoquinol SA (FR) 2025-03-12 EP disclosed
CN-222259316-U PH detection and adjustment system for flunixin synthesis 通辽华旭药业有限公司 2024-12-27 CN disclosed
EP-4466251-A1 TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS TECHFIELDS INC. (US) 2024-11-27 EP disclosed
CN-118515773-B Sulfonamide monoclonal antibody, detection test strip and application thereof 北京纳百生物科技有限公司 2024-10-08 CN disclosed
WO-2022173818-A1 USE OF BILIVERDIN REDUCTASE B INHIBITORS TO ALLOW MALARIA ERADICATION IN PATIENTS WITH G6PD DEFICIENCY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-08-18 WO disclosed
WO-2022173818-A1 USE OF BILIVERDIN REDUCTASE B INHIBITORS TO ALLOW MALARIA ERADICATION IN PATIENTS WITH G6PD DEFICIENCY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-08-18 WO disclosed
CN-114828897-A Modulation of cell viability 麦考瑞大学 2022-07-29 CN disclosed
CN-114716390-A Compositions and methods for treating and/or preventing necrosis of cells or tissue ELA制药有限公司 2022-07-08 CN disclosed
WO-2022112277-A1 METHOD OF TREATMENT OF PAIN THROUGH BUCCAL ADMINISTRATION OF FLUNIXIN INTERVET INTERNATIONAL B.V. (NL) 2022-06-02 WO disclosed
CN-114269324-A Isoxazoline anthelmintic formulations and methods for treating blepharitis 塔苏斯制药有限公司 2022-04-01 CN disclosed
CN-109010916-B Moldable formulations containing oxysterol in acellular tissue matrices 华沙整形外科股份有限公司 2022-03-04 CN disclosed